From: A mixed methods approach to understand variation in lung cancer practice and the role of guidelines
LHIN | Guideline treatment (RCC) | Treated non-RCC | Alternate treatment | No treatment < 180 days of diagnosis | Total nonresected IIIA & IIIB cases |
---|---|---|---|---|---|
1 | 36% | 6% | 27% | 31% | 84 |
2 | 35% | 6% | 24% | 34% | 140 |
3 | 25% | 13% | 34% | 28% | 53 |
4 | 25% | 1% | 41% | 33% | 181 |
5 | 6% | 6% | 39% | 48% | 31 |
6 | 21% | 11% | 32% | 36% | 85 |
7 | 10% | 16% | 35% | 38% | 79 |
8 | 12% | 15% | 27% | 46% | 95 |
9 | 21% | 12% | 25% | 41% | 138 |
10 | 34% | 0% | 35% | 31% | 68 |
11 | 32% | 2% | 41% | 25% | 128 |
12 | 19% | 11% | 38% | 32% | 47 |
13 | 28% | 6% | 46% | 20% | 69 |
14 | 18% | 3% | 50% | 29% | 38 |
Ontario | 25% | 7% | 34% | 34% | 1,236 |